Science & Research
Advancing precision therapeutics for diseases of pathological mineralization
ENPP1 generates PPi from ATP; TNAP hydrolyzes PPi. Their balance governs mineralization.
Pyrophosphate binds to mineralized surfaces, inhibiting further crystal growth.
ENPP1 is the only enzyme that generates extracellular pyrophosphate (PPi), a potent endogenous inhibitor of hydroxyapatite mineralization. Research from the Braddock laboratory at Yale demonstrated that ENPP1 regulates bone mass through both catalysis-dependent and catalysis-independent signaling pathways (Zimmerman et al., J Bone Miner Res 2022). Because pyrophosphate balance governs how and where mineralization occurs, ENPP1 biology has relevance across multiple disorders involving abnormal calcification, impaired tissue repair, or crystal deposition.
Foundational research established that pyrophosphate is the central regulator of acellular cementum formation, with cementoblasts actively modulating local PPi concentrations to control mineralization on tooth root surfaces (Foster et al., PLoS ONE 2012). Subsequent studies showed that counter-regulatory phosphatases TNAP and NPP1 (ENPP1) temporally regulate cementogenesis, with NPP1 expression increasing as cementum matures to restrict further apposition (Foster et al., Int J Oral Sci 2015). Work on hypophosphatasia demonstrated that correcting the phosphate/pyrophosphate ratio rescues mineralization in periodontal ligament cells (Rodrigues et al., J Periodontol 2011) and that HPP-associated pyrophosphate imbalance disrupts odontoblast gene expression and dentin mineralization (Rodrigues et al., J Endod 2012). Together, these findings shaped the thesis that targeted modulation of ENPP1 biology may support tissue restoration across multiple clinical contexts.
Petragen is focused on diseases in which pathological mineralization contributes to progression or unmet clinical burden. This includes periodontal disease, affecting nearly 36 million people in the U.S. where current treatments offer minimal benefit; hypophosphatasia, where current biological treatments can cost up to $2 million per year and require near daily injections; and CPPD, a crystal arthropathy affecting nearly 10 million people with limited disease-modifying options.
Our scientific strategy combines target biology, translational disease selection, formulation and delivery thinking, and practical development paths. We prioritize programs where mechanism, clinical need, and product strategy align.
Each of Petragen’s programs targets a specific aspect of ENPP1 and pyrophosphate biology where the mechanism directly drives disease pathology.
ENPP1 generates pyrophosphate that regulates cementum formation on tooth root surfaces. In periodontal disease, loss of cementum and alveolar bone leads to tooth loosening and loss. Petragen is developing a locally delivered therapeutic that modulates ENPP1 biology to support cementum regeneration and restore the tooth-bone attachment apparatus, targeting the direct pathophysiology rather than downstream inflammation.
Explore Periodontal disease →
HPP is caused by mutations in the ALPL gene encoding alkaline phosphatase (TNAP), the counter-regulatory enzyme to ENPP1 that hydrolyzes pyrophosphate. When TNAP is deficient, excess pyrophosphate accumulates and inhibits skeletal and dental mineralization. Petragen is developing a small molecule approach that targets this phosphate/pyrophosphate imbalance to restore normal mineralization without the burden and cost of current biological therapies.
Explore HPP →
CPPD arises from the deposition of calcium pyrophosphate crystals in cartilage and periarticular tissues, directly driven by excess extracellular pyrophosphate. ENPP1 is the primary enzymatic source of this pyrophosphate. Petragen is targeting the ENPP1-mediated overproduction of pyrophosphate to reduce crystal formation at its source, aiming to deliver a genuinely disease-modifying therapy rather than treating downstream inflammation alone.
Explore CPPD →This website may include forward-looking statements regarding investigational programs that are subject to risks and uncertainties.